A new approach to reduce toxicities and to improve bioavailabilities of platinum-containing anti-cancer nanodrugs

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Li ^a   Ye, Qing ^a   Lu, Maggie ^b   Lo, Ya Chin ^b   Hsu, Yuan Hung ^b   Wei, Ming Cheng ^b   Chen, Yu Hsiang ^b   Lo, Shen Chuan ^b   Wang, Shian Jy ^b   Bain, Daniel J ^c   Ho, Chien ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYALURONIC ACID; NANOPARTICLE; PLATINUM; POLYMER;

ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; LIVER; MALE; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; RAT; SPLEEN; THERANOSTIC NANOMEDICINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; HYALURONIC ACID; LIVER; MALE; NANOPARTICLES; PLATINUM; POLYMERS; RATS; SPLEEN; THERANOSTIC NANOMEDICINE;

EID: 84930613688     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10881     Document Type: Article

References (43)

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians 65, 5-29 (2015).
2. Wheate, N. J., Walker, S., Craig, G. E. & Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton transactions 39, 8113-8127 (2010).
3. Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73, 994-1007 (2008).
4. McWhinney, S. R., Goldberg, R. M. & McLeod, H. L. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8, 10-16 (2009).
5. Ulusakarya, A., et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Medical oncology 27, 1425-1426 (2010).
6. Negro, A., Grasselli, C. & Galli, P. Oxaliplatin-induced proximal renal tubular acidosis. Internal and emergency medicine 5, 267-268 (2010).
7. Joybari, A.Y., et al. Oxaliplatin-induced renal tubular vacuolization. The Annals of pharmacotherapy 48, 796-800 (2014).
8. Yao, X., Panichpisal, K., Kurtzman, N. & Nugent, K. Cisplatin nephrotoxicity: a review. The American journal of the medical sciences 334, 115-124 (2007).
9. Ludwig, T., Riethmuller, C., Gekle, M., Schwerdt, G. & Oberleithner, H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66, 196-202 (2004).
10. Stefanowicz, J., Owczuk, R., Izycka-Swieszewska, E., Ruckemann-Dziurdzinska, K. & Balcerska, A. Nephrotoxicity of platinum derivatives in children-A review of the literature. Wspolczesna Onkol 15, 74-79 (2011).
11. Labaye, J., et al. Renal toxicity of oxaliplatin. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association-European Renal Association 20, 1275-1276 (2005).
12. Heger, M. Amgen deal triggers watchful waiting in targeted nanomedicine. Nat Med 19, 120 (2013).
13. Chow, E. K. & Ho, D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 5, 216rv214 (2013).
14. Chauhan, V. P. & Jain, R. K. Strategies for advancing cancer nanomedicine. Nat Mater 12, 958-962 (2013).
15. Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu Rev Med 63, 185-198 (2012).
16. Zamboni, W. C., et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res 18, 3229-3241 (2012).
17. Cabral, H., et al. Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci USA 110, 11397-11402 (2013).
18. Cabral, H., Nishiyama, N., Okazaki, S., Koyama, H. & Kataoka, K. Preparation and biological properties of dichloro(1, 2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 101, 223-232 (2005).
19. Murakami, M., et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med 3, 64ra62 (2011).
20. Oberoi, H. S., et al. Preparation and In Vivo Evaluation of Dichloro(1, 2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles. Chemother Res Pract 2012, 905796 (2012).
21. Wu, H., et al. Polymeric micelles loaded with platinum anticancer drugs target preangiogenic micrometastatic niches associated with inflammation. J Control Release 189, 1-10 (2014).
22. Albanese, A., Tang, P. S. & Chan, W. C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14, 1-16 (2012).
23. Neuberger, T., Schopf, B., Hofman, H., Hofman, M. & Rechenberg, B. Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. Journal of Magnetism and Magnetic Materials 293, 483-496 (2005).
24. Arvizo, R. R., et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 6, e24374 (2011).
25. Maesaki, S. Drug delivery system of anti-fungal and parasitic agents. Curr Pharm Des 8, 433-440 (2002).
26. Romberg, B., Hennink, W. E. & Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 25, 55-71 (2008).
27. Jokerst, J. V., Lobovkina, T., Zare, R. N. & Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 6, 715-728 (2011).
28. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5, 505-515 (2008).
29. Nugent, K. M. Intralipid effects on reticuloendothelial function. J Leukoc Biol 36, 123-132 (1984).
30. Vilaro, S. & Llobera, M. Uptake and metabolism of Intralipid by rat liver: an electron-microscopic study. J Nutr 118, 932-940 (1988).
31. Liu, L., et al. Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano-And micron-sized superparamagnetic iron-oxide particles upon pre-Treatment with Intralipid. Biochim Biophys Acta 1830, 3447-3453 (2013).
32. Ho, C., Liu, L., Wu, Y. J., Hitchens, K., & Ye, Q. inventors; Carnegie Mellon University, assignee. Methods and materials for reducing reticuloendothelial system clearance of particles from a subject. United States patent application: PCT/US2013/058587. 2013 Sep 6.
33. Kamaly, N., et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci USA 110, 6506-6511 (2013).
34. Oberoi, H. S., Nukolova, N. V., Kabanov, A. V. & Bronich, T. K. Nanocarriers for delivery of platinum anticancer drugs. Advanced drug delivery reviews 65, 1667-1685 (2013).
35. Biazar, E., et al. The effect of acetaminophen nanoparticles on liver toxicity in a rat model. Int J Nanomedicine 5, 197-201 (2010).
36. Fraser, I., Pearson, H., Bowry, V. & Bell, P. R. The intravenous intralipid tolerance test. J Leukoc Biol 36, 647-649 (1984).
37. Hansen, L. M., Hardie, B. S. & Hidalgo, J. Fat emulsion for intravenous administration: clinical experience with intralipid 10%. Annals of surgery 184, 80-88 (1976).
38. Sriramoju, B., Kanwar, R. K. & Kanwar, J. R. Nanomedicine Based Nanoparticles for Neurological Disorders. Curr Med Chem. DOI: 10.2174/0929867321666140716095644 (2014).
39. Lobatto, M. E., Fuster, V., Fayad, Z. A. & Mulder, W. J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nature reviews. Drug discovery 10, 835-852 (2011).
40. Mulder, W. J., Jaffer, F. A., Fayad, Z. A. & Nahrendorf, M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med 6, 239sr231 (2014).
41. Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced drug delivery reviews 65, 71-79 (2013).
42. Kim, Y., et al. Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc Natl Acad Sci USA 111, 1078-1083 (2014).
43. Esteban-Fernandez, D., Verdaguer, J. M., Ramirez-Camacho, R., Palacios, M. A. & Gomez-Gomez, M. M. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol 32, 140-146 (2008).